Bookbuilding IPO | ₹4,326 Cr | Listed at BSE, NSE | Tue, Apr 25, 2023 - Thu, Apr 27, 2023
Mankind Pharma IPO is a book build issue of ₹4,326.36 crores. The issue is entirely an offer for sale of 4.01 crore shares of ₹4,326.36 crore.
Mankind Pharma IPO bidding started from Apr 25, 2023 and ended on Apr 27, 2023. The allotment for Mankind Pharma IPO was finalized on May 3, 2023. The shares got listed on BSE, NSE on May 9, 2023.
Mankind Pharma IPO price band is set at ₹1,080 per share. The lot size for an application is 13. The minimum amount of investment required by an retail is ₹14,040 (13 shares) (based on upper price). The lot size investment for sNII is 15 lots (195 shares), amounting to ₹2,10,600, and for bNII, it is 72 lots (936 shares), amounting to ₹10,10,880.
Kotak Mahindra Capital Co.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Mankind Pharma IPO RHP for detailed Information.
IPO Open
Tue, Apr 25, 2023
IPO Close
Thu, Apr 27, 2023
Issue Price
₹1080 per share
Market Cap (Pre-IPO)
₹43,263.60 Cr
| IPO Date | 25 to 27 Apr, 2023 |
| Listed on | Tue, May 9, 2023 |
| Face Value | ₹1 per share |
| Price Band | ₹1026 to ₹1080 |
| Issue Price | ₹1080 per share |
| Lot Size | 13 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 4,00,58,844 shares (agg. up to ₹4,326 Cr) |
| Offer for Sale | 4,00,58,844 shares of ₹1 (agg. up to ₹4,326 Cr) |
| Share Holding Pre Issue | 40,05,88,440 shares |
| Share Holding Post Issue | 40,05,88,440 shares |
| BSE Script Code / NSE Symbol | 543904 / MANKIND |
| ISIN | INE634S01028 |
Mankind Pharma IPO offers total 4,00,58,844 shares. Out of which 2,00,29,421 (50.00%) allocated to QIB, 80,11,769 (20.00%) allocated to QIB (Ex- Anchor), 60,08,827 (15.00%) allocated to NII 1,40,20,596 (35.00%) allocated to RII and 1,20,17,652 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 2,00,29,421 (50.00%) | NA |
| − Anchor Investor Shares Offered | 1,20,17,652 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 80,11,769 (20.00%) | NA |
| NII (HNI) Shares Offered | 60,08,827 (15.00%) | NA |
| − bNII > ₹10L | 40,05,885 (10.00%) | 20,543 |
| − sNII < ₹10L | 20,02,942 (5.00%) | 10,271 |
| Retail Shares Offered | 1,40,20,596 (35.00%) | 10,78,507 |
| Total Shares Offered | 4,00,58,844 (100.00%) |
Investors can bid for a minimum of 13 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹1,96,560 |
| S-HNI (Min) | 15 | 195 | ₹2,10,600 |
| S-HNI (Max) | 71 | 923 | ₹9,96,840 |
| B-HNI (Min) | 72 | 936 | ₹10,10,880 |
Mankind Pharma IPO raises ₹1,297.91 crore from anchor investors. Mankind Pharma IPO Anchor bid date is April 24, 2023.
📝 Anchor Investors Letter (PDF)
| Bid Date | Mon, Apr 24, 2023 |
| Shares Offered | 1,20,17,652 |
| Anchor Portion (₹ Cr.) | 1,297.91 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jun 2, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Aug 1, 2023 |
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.
Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.
As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
| Period Ended | 31 Dec 2022 | 31 Mar 2022 | 31 Dec 2021 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|---|---|
| Assets | 9,273.75 | 9,147.74 | 8,043.88 | 6,372.63 | 5,073.29 |
| Total Income | 6,777.82 | 7,977.58 | 6,218.29 | 6,385.38 | 5,975.65 |
| Profit After Tax | 1,015.98 | 1,452.96 | 1,260.24 | 1,293.03 | 1,056.15 |
| NET Worth | 7,145.89 | 6,155.23 | 5,965.46 | 4,722.00 | 3,485.31 |
| Reserves and Surplus | 7,094.12 | 6,106.06 | 5,916.86 | 4,674.39 | 3,436.34 |
| Total Borrowing | 167.93 | 868.03 | 268.70 | 234.53 | 126.92 |
| Amount in ₹ Crore | |||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Carry out the Offer for Sale of 40,058,844Equity Shares by the Selling Shareholders aggregating to ₹43,263.55 million | |
| 2 | Achieve the benefits of listing the Equity Shares on the Stock Exchanges. For further details |
| KPI | |
|---|---|
| ROE | 27.60% |
| ROCE | 26.10% |
| RoNW | 27.70% |
| PAT Margin | 18.67% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 33.20 | |
| P/E (x) | 32.5 | |
| Promoter Holding | 79.00% | 76.50% |
| Market Cap | ₹43,263.60 Cr. |
The Mankind Pharma IPO is subscribed 15.32 times on April 27, 2023 7:02:00 PM (Day 3). The public issue subscribed 0.92 times in the retail category, 49.16 times in the QIB category, and 3.8 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 49.16 | 80,11,769 | 39,38,34,103 |
| NII | 3.8 | 60,08,827 | 2,28,22,761 |
| bNII (bids above ₹10L) | 4.99 | 40,05,885 | 2,00,00,500 |
| sNII (bids below ₹10L) | 1.41 | 20,02,942 | 28,22,261 |
| Retail | 0.92 | 1,40,20,596 | 1,28,56,038 |
| Total | 15.32 | 2,80,41,192 | 42,95,12,902 |
Total Application : 4,62,789
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs and commissions(including underwriting commission, brokerage and selling commission) | 102.23 |
| 2 | Commission/processing fee for SCSBs, Sponsor Bank and Banker to the Offer andBidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 0.85 |
| 3 | Fees payable to the Registrar to the Offer | 1.28 |
| 4 | Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and otherregulatory expenses | 10.74 |
| 5 | Advertising and marketing expenses | 13.12 |
| 6 | Printing and distribution of Offer related stationery | 3.14 |
| 7 | Fees payableto legal counsel; and | 10.62 |
| 8 | Fees payable to other parties, including but not limited toauditors, independentchartered accountant, industryexpert, intellectual property consultant, independent chartered engineer and ROC consultant | 20.61 |
| 9 | Miscellaneous | 9.05 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,080.00 | ₹1,080.00 |
| Open | ₹1,300.00 | ₹1,300.00 |
| Low | ₹1,300.00 | ₹1,300.00 |
| High | ₹1,430.00 | ₹1,430.00 |
| Last Trade | ₹1,424.05 | ₹1,080.00 |
Mankind Pharma IPO is a main-board IPO of 4,00,58,844 equity shares of the face value of ₹1 aggregating up to ₹4,326 Crores. The issue is priced at ₹1080 per share. The minimum order quantity is 13.
The IPO opens on Tue, Apr 25, 2023, and closes on Thu, Apr 27, 2023.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Mankind Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Mankind Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Mankind Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Mankind Pharma IPO opens on Tue, Apr 25, 2023 and closes on Thu, Apr 27, 2023.
Mankind Pharma IPO lot size is 13, and the minimum amount required for application is ₹14,040.
You can apply in Mankind Pharma IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Mankind Pharma IPO will be done on Wednesday, May 3, 2023, and the allotted shares will be credited to your demat account by Fri, May 5, 2023. Check the Mankind Pharma IPO allotment status.
The Mankind Pharma IPO listing date is on Tue, May 9, 2023.
